The estimated Net Worth of Mark Sullivan is at least $1.23 Milione dollars as of 2 March 2023. Mr. Sullivan owns over 298,175 units of Sesen Bio stock worth over $266,824 and over the last 5 years he sold SESN stock worth over $23,500. In addition, he makes $937,718 as General Counsel e Corporate Secretary at Sesen Bio.
Sign up
Mr. Sullivan SESN stock SEC Form 4 insiders trading
Mark has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 298,175 units of SESN stock worth $175,923 on 2 March 2023.
The largest trade he's ever made was exercising 298,175 units of Sesen Bio stock on 2 March 2023 worth over $175,923. On average, Mark trades about 56,334 units every 2 days since 2019. As of 2 March 2023 he still owns at least 423,530 units of Sesen Bio stock.
You can see the complete history of Mr. Sullivan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Sullivan biography
Mark R. Sullivan serves as General Counsel, Corporate Secretary of the Company. From April 2018 to August 2019 he served as our Acting General Counsel. From August 2012 through March 2018, he served as a private consultant to life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. (Nasdaq: MODL), formerly MedQuist, Inc., a leading healthcare IT company, from September 2006 until July 2012 when MModal was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. From August 2004 until September 2006, Mr. Sullivan was the Acting General Counsel of MModal MQ Inc. Between March 2003 and August 2004, Mr. Sullivan served as Associate General Counsel and Assistant Secretary of MModal MQ Inc. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP from 2000 to 2003, and Drinker Biddle & Reath LLP from 1998 to 2000. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.
What is the salary of Mark Sullivan?
As the General Counsel e Corporate Secretary of Sesen Bio, the total compensation of Mark Sullivan at Sesen Bio is $937,718. There are 1 executives at Sesen Bio getting paid more, with Thomas Cannell having the highest compensation of $1,404,240.
How old is Mark Sullivan?
Mark Sullivan is 48, he's been the General Counsel e Corporate Secretary of Sesen Bio since 2019. There are 12 older and 4 younger executives at Sesen Bio. The oldest executive at Sesen Bio Inc. is Dr. Glen C. MacDonald, 70, who is the Chief Technology Officer.
What's Mark Sullivan's mailing address?
Mark's mailing address filed with the SEC is C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Insiders trading at Sesen Bio
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes e Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
What does Sesen Bio do?
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
What does Sesen Bio's logo look like?
Complete history of Mr. Sullivan stock trades at Sesen Bio
Sesen Bio executives and stock owners
Sesen Bio executives and other stock owners filed with the SEC include:
-
Thomas Cannell,
President, Chief Executive Officer, Director -
Mark Sullivan,
General Counsel, Corporate Secretary -
Dr. Thomas R. Cannell,
Pres, CEO & Director -
Monica Forbes,
Chief Financial Officer, Treasurer -
Monica Forbes,
CFO & Treasurer -
Dr. Glen C. MacDonald,
Chief Technology Officer -
Jason Keyes,
Independent Director -
Carrie Bourdow,
Independent Director -
Jane Henderson,
Independent Director -
Jay Duker,
Independent Chairman of the Board -
Glen MacDonald,
Chief Technology Officer -
Daniel Lynch,
Independent Director -
John Knighton,
VP & Chief Compliance Officer -
Dr. Gregory L. Verdine Ph.D.,
Co-Founder -
Dr. David Brooks,
Sr. VP of Clinical Devel. -
Julie Hoff,
VP of HR -
Steve Barbera,
VP of Market Access -
Mark R. Sullivan,
Gen. Counsel & Corp. Sec. -
Erin Clark,
VP of Corp. Strategy & Investor Relations -
Elly Ryu,
Corp. Controller & Principal Accounting Officer -
Dr. Gregory L. Verdine,
Co-Founder -
Minori Rosales,
Chief Development Officer -
Leslie Dan,
Director -
Paul G Chaney,
Director -
Abbie Celniker,
Director -
Stephen A Hurly,
President and CEO -
Wendy L Dixon,
Director -
Dennis Kim,
Chief Medical Officer -
Richard F Fitzgerald,
Chief Financial Officer -
Peter Honig,
Director -
Michael A. S. Jewett,
Director -
Kirstin Anderson,
Principal Accounting Officer -
Elly Ryu,
Principal Accounting Officer